2025 American Society of Clinical Oncology Annual Meeting Abstract

Impact of CAR T cell therapy product in the clinical outcome of patients with relapsed/refractory diffuse large B-cell lymphoma

2025 American Society of Clinical Oncology Annual Meeting Abstract

Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO

2025 American Society of Clinical Oncology Annual Meeting Abstract

Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study

HemaSphere

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Nature Cancer

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

2025 Transplantation & Cellular Therapy Meetings Abstract

Tandem CD20-CD19-directed non-cryopreserved CAR T cells - zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma - interim results from a phase 2 pivotal study (DALY II USA)

The Lancet

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

OncLive

ctDNA testing joins NCCN Guidelines for MRD assessment in DLBCL

Journal of Clinical Oncology

Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes